MEDP

Medpace Holdings Inc

Add to Watchlist

Advanced Chart

449.770

+15.42(3.550%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

451.0688

Open

436.780

VWAP

446.22

Vol

567.47K

Mkt Cap

12.64B

Low

436.780

Amount

253.22M

EV/EBITDA(TTM)

24.00

Total Shares

30.98M

12.16B

EV/OCF(TTM)

19.79

P/S(TTM)

6.05

Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

641.69M

+14.88%

661.24M

+23.23%

641.70M

+20.32%

Estimates Revision

The market is revising Upward the revenue expectations for Medpace Holdings, Inc. (MEDP) for FY2025, with the revenue forecasts being adjusted by 12.81% over the past three months. During the same period, the stock price has changed by 43.36%.

Revenue Estimates for FY2025

Revise Upward

+12.81%

In Past 3 Month

Stock Price

Go Up

+43.36%

In Past 3 Month

9 Analyst Rating

-8.51% Downside

Wall Street analysts forecast MEDP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MEDP is 411.50 USD with a low forecast of 300.00 USD and a high forecast of 510.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

6 Hold

2 Sell

Hold

-8.51% Downside

Current: 449.770

Low

300.00

Averages

411.50

High

510.00

-8.51% Downside

Current: 449.770

Low

300.00

Averages

411.50

High

510.00

UBS

Dan Leonard

Neutral -> Sell

downgrade

$300 -> $305

2025-07-29

Reason

UBS

Dan Leonard

Price Target

$300 -> $305

2025-07-29

downgrade

Neutral -> Sell

Reason

UBS analyst Dan Leonard downgraded Medpace to Sell from Neutral with a price target of $305, up from $300. The firm views the company's near- and mid-term targets as "overly ambitious" against a "weak "industry backdrop. Medpace's Q2 bookings improved materially, but further improvement towards Street estimates and the company's targets would require record bookings in the second half of 2025 despite weak biotech capital markets, clinical trial starts, muted hiring, and other cautionary signals, the analyst tells investors in a research note.

Mizuho

Outperform

upgrade

$328 -> $510

2025-07-25

Reason

Mizuho

Price Target

$328 -> $510

2025-07-25

upgrade

Outperform

Reason

Mizuho raised the firm's price target on Medpace to $510 from $328 and keeps an Outperform rating on the shares. The company's booking trends were stable in the quarter, much better than feared, the analyst tells investors in a research note. The firm says that when coupled with improved cancelation rates and an improvement in trial delays, there is increased earnings visibility for 2026.

Barclays

Luke Sergott

Equal Weight

maintain

$300 -> $450

2025-07-23

Reason

Barclays

Luke Sergott

Price Target

$300 -> $450

2025-07-23

maintain

Equal Weight

Reason

Barclays analyst Luke Sergott raised the firm's price target on Medpace to $450 from $300 and keeps an Equal Weight rating on the shares. The firm says the biggest question going forward is whether the company's strong Q2 bookings environment is sustainable to offset elevated burn-rates.

TD Cowen

Hold

Sell

downgrade

$283 -> $366

2025-07-23

Reason

TD Cowen

Price Target

$283 -> $366

2025-07-23

downgrade

Hold

Sell

Reason

TD Cowen downgraded Medpace to Sell from Hold with a price target of $366, up from $283.

Deutsche Bank

Hold

upgrade

$270 -> $430

2025-07-23

Reason

Deutsche Bank

Price Target

$270 -> $430

2025-07-23

upgrade

Hold

Reason

Deutsche Bank raised the firm's price target on Medpace to $430 from $270 and keeps a Hold rating on the shares.

TD Cowen

Hold

Sell

downgrade

$283 -> $366

2025-07-23

Reason

TD Cowen

Price Target

$283 -> $366

2025-07-23

downgrade

Hold

Sell

Reason

TD Cowen downgraded Medpace to Sell from Hold with a price target of $366, up from $283. The post-earnings 55% share rally yesterday was due to short covering and not a change in the company's fundamentals, the analyst tells investors in a research note. The firm says that the shares, trading at 31-times its higher 2026 earnings estimates, are overvalued relative to Medpace's expected growth. NULLtheless, TD admits the company's' mix shift towards faster burning therapeutic categories, like metabolic, could be more sustainable than previously thought.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Medpace Holdings Inc (MEDP.O) is 29.22, compared to its 5-year average forward P/E of 29.73. For a more detailed relative valuation and DCF analysis to assess Medpace Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

29.73

Current PE

29.22

Overvalued PE

35.16

Undervalued PE

24.30

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

22.00

Current EV/EBITDA

22.64

Overvalued EV/EBITDA

25.78

Undervalued EV/EBITDA

18.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

4.40

Current PS

4.66

Overvalued PS

5.19

Undervalued PS

3.61